Stock Detail
Videos
NeurAxis (NRXS) Fireside Chat
NeurAxis, Inc. (NYSE American: NRXS) is a medical technology company focused on neuromodulation therapies to address chronic and debilitating conditions in children and adults. This fireside chat was recorded during the Lytham Partners Fall 2025 Investor Conference.
NeurAxis (NRXS) Company Webcast
NeurAxis, Inc. (NYSE American: NRXS) is a medical technology company focused on neuromodulation therapies to address chronic and debilitating conditions in children and adults. This company webcast was recorded during the Lytham Partners Spring 2025 Investor...
NeurAxis, Inc. (NRXS) Company Webcast
This company webcast features NeurAxis, Inc. (NYSE American: NRXS). NeurAxis is a medical technology company focused on neuromodulation therapies to address chronic and debilitating conditions in children and adults. This company webcast was recorded during the Lytham...
News
NeurAxis Achieves Major Milestone with AMA Category I CPT® Code Now in Effect, Establishing a Permanent Reimbursement Pathway
The new CPT code reflects the latest efficacious medical care available to patients, facilitating adoption and utilization.The assignment of a Category I CPT® code demonstrates a strong message to payers, both commercial and government, that there is now a path...
NeurAxis Achieves Medical Coverage Policy Milestone, Expanding Access to Approximately 45 million additional Covered Lives
Total national coverage footprint for PENFS increases to roughly 100 million covered livesCARMEL, Ind., Dec. 19, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. ("NeurAxis" or the "Company") (NYSE American: NRXS), a medical technology company commercializing neuromodulation...
NeurAxis Secures Veterans Affairs Federal Supply Schedule Contract, Broadening Access to More Patients with Functional Abdominal Pain
CARMEL, Ind., Dec. 01, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. ("NeurAxis" or the "Company") (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, today announced...